2017 / 02

Следующая статья
DOI: 10.24075/brsmu.2017-02-03

МНЕНИЕ

Серин-треониновые протеинкиназы бактерий — потенциальная мишень для регуляции состава микробиоты человека

Н. В. Захаревич1, В. Н. Даниленко2
Информация об авторах

1 Лаборатория генетики микроорганизмов, Институт общей генетики имени Н. И. Вавилова РАН, Москва

2 Кафедра биоинформатики, факультет биологической и медицинской физики,
Московский физико-технический институт (государственный университет), Долгопрудный

Для корреспонденции: Захаревич Наталья Владимировна
ул. Губкина, д. 3, г. Москва, 119991; ur.xednay@hciverahkaz

Информация о статье

Вклад всех авторов в работу равнозначен: подбор и анализ литературы, планирование структуры статьи, интерпретация данных литературы, подготовка черновика рукописи, внесение исправлений.

Статья получена: 28.03.2017 Статья принята к печати: 07.04.2017 Опубликовано online: 31.05.2017
|
  1. Янковский Д. С. Состав и функции микробиоценозов различных биотопов человека. Здоровье женщины. 2003; 4 (16): 145–58.
  2. Oriach CS, Robertson RC, Stanton C, Cryan JF, Dinan TG. Food for thought: The role of nutrition in the microbiota-gut–brain axis. Clin Nutr Exp. 2016; (6): 25–38.
  3. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez- Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012 May 9; 486 (7402): 222–7.
  4. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy DN. Role of the normal gut microbiota. World J Gastroenterol. 2015 Aug 7; 21 (29): 8787–803.
  5. Аверина О. В., Даниленко В. Н. Микробиота кишечника человека: роль в становлении и функционировании нервной системы. Микробиология. 2017; 86 (1): 5–24.
  6. Hemarajata P, Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol. 2013 Jan; 6 (1): 39–51.
  7. Kamada N, Chen GY, Inohara N, Núñez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013 Jul; 14 (7): 685–90.
  8. DuPont AW, DuPont HL. The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol. 2011 Aug 16; 8 (9): 523–31.
  9. Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010 Jul; 90 (3): 859–904.
  10. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012 Oct; 13 (10): 701–12.
  11. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol. 2011 Jan; 12 (1): 5–9.
  12. Salim SY, Kaplan GG, Madsen KL. Air pollution effects on the gut microbiota: A link between exposure and inflammatory disease. Gut Microbes. 2014 Mar–Apr; 5 (2): 215–9.
  13. Bested AC, Logan AC, Selhub EM. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part III — convergence toward clinical trials. Gut Pathog. 2013 Mar 16; 5 (1): 4.
  14. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012 Oct; 13 (10): 701–12.
  15. Shetty SA, Hugenholtz F, Lahti L, Smidt H, de Vos WM. Intestinal microbiome landscaping: insight in community assemblage and implications for microbial modulation strategies. FEMS Microbiol Rev. 2017 Mar 1; 41 (2): 182–99.
  16. Kang SS, Jeraldo PR, Kurti A, Miller MEB, Cook MD, Whitlock K, et al. Diet and exercise orthogonally alter the gut microbiome and reveal independent associations with anxiety and cognition. Mol Neurodegener. 2014 Sep 13; 9: 36.
  17. Kobir A, Shi L, Boskovic A, Grangeasse C, Franjevic D, Mijakovic I. Protein phosphorylation in bacterial signal transduction. Biochim Biophys Acta. 2011 Oct; 1810 (10): 989–94.
  18. Ge R, Shan W. Bacterial Phosphoproteomic Analysis Reveals the Correlation Between Protein Phosphorylation and Bacterial Pathogenicity. Genomics Proteomics Bioinformatics. 2011 Oct; 9 (4–5): 119–27.
  19. Zakharevich NV, Osolodkin DI, Artamonova II, Palyulin VA, Zefirov NS, Danilenko VN. Signatures of the ATP-binding pocket as a basis for structural classification of the serine/threonine protein kinases of gram-positive bacteria. Proteins. 2012 May; 80 (5): 1363–76.
  20. Danilenko VN, Osolodkin DI, Lakatosh SA, Preobrazhenskaya MN, Shtil AA. Bacterial eukaryotic type serine-threonine protein kinases: from structural biology to targeted anti-infective drug design. Curr Top Med Chem. 2011; 11 (11): 1352–69.
  21. Av-Gay Y, Everett M. The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis. Trends Microbiol. 2000 May; 8 (5): 238–44.
  22. Leonard CJ, Aravind L, Koonin EV. Novel families of putative protein kinases in bacteria and archaea: evolution of the “eukaryotic” protein kinase superfamily. Genome Res. 1998 Oct; 8 (10): 1038–47.
  23. Shi L, Potts M, Kennelly PJ. The serine, threonine, and/or tyrosine- specific protein kinases and protein phosphatases of prokaryotic organisms: a family portrait. FEMS Microbiol Rev. 1998 Oct; 22 (4): 229–53.
  24. Petrícková K, Petrícek M. Eukaryotic-type protein kinases in Streptomyces coelicolor: variations on a common theme. Microbiology. 2003 Jul; 149 (Pt 7): 1609–21.
  25. Cozzone AJ. Role of protein phosphorylation on serine/threonine and tyrosine in the virulence of bacterial pathogens. J Mol Microbiol Biotechnol. 2005; 9 (3–4): 198–213.
  26. Molle V, Kremer L. Division and cell envelope regulation by Ser/Thr phosphorylation: Mycobacterium shows the way. Mol Microbiol. 2010 Mar; 75 (5): 1064–77.
  27. Ruggiero A, De Simone P, Smaldone G, Squeglia F, Berisio R. Bacterial cell division regulation by Ser/Thr kinases: a structural perspective. Curr Protein Pept Sci. 2012 Dec; 13 (8): 756–66.
  28. Elizarov SM, Mironov VA, Danilenko VN. Calcium-induced alterations in the functioning of protein serine/threonine and tyrosine kinases in Streptomyces fradiae cells. IUBMB Life. 2000 Aug; 50 (2): 139–43.
  29. Hussain H, Branny P, Allan E. A eukaryotic-type serine/ threonine protein kinase is required for biofilm formation, genetic competence, and acid resistance in Streptococcus mutans. J Bacteriol. 2006 Feb; 188 (4): 1628–32.
  30. Neu JM, MacMillan SV, Nodwell JR, Wright GD. StoPK-1, a serine/ threonine protein kinase from the glycopeptide antibiotic producer Streptomyces toyocaensis NRRL 15009, affects oxidative stress response. Mol Microbiol. 2002 Apr; 44 (2): 417–30.
  31. Madec E, Laszkiewicz A, Iwanicki A, Obuchowski M, Séror S. Characterization of a membrane-linked Ser/Thr protein kinase in Bacillus subtilis, implicated in developmental processes. Mol Microbiol. 2002 Oct; 46 (2): 571–86.
  32. Rajagopal L, Vo A, Silvestroni A, Rubens CE. Regulation of cytotoxin expression by converging eukaryotic-type and two- component signaling mechanisms in Streptococcus agalactiae. Mol Microbiol. 2006 Nov; 62 (4): 941–57.
  33. Wiley DJ, Nordfeldth R, Rosenzweig J, DaFonseca CJ, Gustin R, Wolf-Watz H, et al. The Ser/Thr kinase activity of the Yersinia protein kinase A (YpkA) is necessary for full virulence in the mouse, mollifying phagocytes, and disrupting the eukaryotic cytoskeleton. Microb Pathog. 2006 May; 40 (5): 234–43.
  34. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1; 28 (1): 235–42.
  35. Pereira SF, Goss L, Dworkin J. Eukaryote-like serine/threonine kinases and phosphatases in bacteria. Microbiol Mol Biol Rev. 2011 Mar; 75 (1): 192–212.
  36. Hanks SK. Genomic analysis of the eukaryotic protein kinase superfamily: a perspective. Genome Biol. 2003; 4 (5): 111.
  37. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005 Jun 10; 308 (5728): 1635–8.
  38. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the Human Infant Intestinal Microbiota. PLoS Biol. 2007 Jul; 5 (7): e177.
  39. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut Microbiome. Nature. 2011 May 12; 473 (7346): 174–80.
  40. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature. 2006 Dec 21; 444 (7122): 1022–3.
  41. Zoetendal EG, Akkermans AD, De Vos WM. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol. 1998 Oct; 64 (10): 3854–9.
  42. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012 Apr 16; 13 (9): R79.
  43. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012 Jun 13; 486 (7402): 207–14.
  44. Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut. 2011 May; 60 (5): 631–7.
  45. Statnikov A, Alekseyenko AV, Li Z, Henaff M, Perez-Perez GI, Blaser MJ, et al. Microbiomic Signatures of Psoriasis: Feasibility and Methodology Comparison. Sci Rep. 2013; 3: 2620.
  46. Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults. PLoS ONE. 2010 Feb 5; 5 (2): e9085.
  47. Zeuthen LH, Christensen HR, Frøkiaer H. Lactic acid bacteria inducing a weak interleukin-12 and tumor necrosis factor alpha response in human dendritic cells inhibit strongly stimulating lactic acid bacteria but act synergistically with gram-negative bacteria. Clin Vaccine Immunol. 2006 Mar; 13 (3): 365–75.
  48. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010 May; 22 (5): 512–9, e114–5.
  49. Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012 Oct; 9 (10): 599– 608.
  50. Malhotra V, Arteaga-Cortés LT, Clay G, Clark-Curtiss JE. Mycobacterium tuberculosis protein kinase K confers survival advantage during early infection in mice and regulates growth in culture and during persistent infection: implications for immune modulation. Microbiology. 2010 Sep; 156 (Pt 9): 2829–41.
  51. Malhotra V, Okon BP, Clark-Curtiss JE. Mycobacterium tuberculosis Protein Kinase K Enables Growth Adaptation through Translation Control. J Bacteriol. 2012 Aug; 194 (16): 4184–96.
  52. Gopalaswamy R, Narayanan S, Chen B, Jacobs WR, Av-Gay Y. The serine/threonine protein kinase PknI controls the growth of Mycobacterium tuberculosis upon infection. FEMS Microbiol Lett. 2009 Jun; 295 (1): 23–9.
  53. Ohlsen K, Donat S. The impact of serine/threonine phosphorylation in Staphylococcus aureus. Int J Med Microbiol. 2010 Feb; 300 (2–3): 137–41.
  54. Jers C, Kobir A, Søndergaard EO, Jensen PR, Mijakovic I. Bacillus subtilis Two-Component System Sensory Kinase DegS Is Regulated by Serine Phosphorylation in Its Input Domain. PLoS ONE. 2011 Feb 3; 6 (2): e14653.
  55. Форстер К. Дж. (US), Эрност М. Дж. (US), Ван Ц. (US), Дэвис Р. Дж. (US), авторы; Вертекс Фармасьютикалз Инкорпорейтед (US), патентообладатель. Триазолы, используемые в качестве ингибиторов протеинкиназ. Патент РФ RU 2393155. 27 июня 2010 г.
  56. Потехина Е. С., Надеждина Е. С. Митоген-активируемые протеинкиназные каскады и участие в них Ste20-подобных протеинкиназ. Успехи биол. хим. 2002; 42: 235–56.
  57. Dan C, Nath N, Liberto M, Minden A. PAK5, a New Brain-Specific Kinase, Promotes Neurite Outgrowth in N1E-115 Cells. Mol Cell Biol. 2002 Jan; 22 (2): 567–77.
  58. Hergovich A, Stegert MR, Schmitz D, Hemmings BA. NDR kinases regulate essential cell processes from yeast to humans. Nat Rev Mol Cell Biol. 2006 Apr; 7 (4): 253–64.
  59. Клатт А. Р. (DE), Бартник Э. (DE), Чех Й. (DE), Леберер Э. (DE), Леойв Т. (DE), Баррадо С. (DE), авторы; Санофи-Авентис Дойчланд Гмбх (DE), патентообладатель. Применение ингибитора рак для лечения заболевания суставов. Патент РФ RU 2360696. 10 июля 2009 г.
  60. Wehenkel A, Bellinzoni M, Graña M, Duran R, Villarino A, Fernandez P, et al. Mycobacterial Ser/Thr protein kinases and phosphatases: physiological roles and therapeutic potential. Biochim Biophys Acta. 2008 Jan; 1784 (1): 193–202.
  61. Cohen P. Protein kinases — the major drug targets of the twenty- first century? Nat Rev Drug Discov. 2002 Apr; 1 (4): 309–15.
  62. Osolodkin DI, Zakharevich NV, Palyulin VA, Danilenko VN, Zefirov NS. Bioinformatic analysis of glycogen synthase kinase 3: human versus parasite kinases. Parasitology. 2011 May; 138 (6): 725–35.